COMPARE · Data as of August 27, 2026
ELVN vs EXEL
Verdict: Side-by-side breakdown using the Bull Rankings model. ELVN scored 19.3, EXEL scored 73.9 — EXEL leads.
Compare another set
ELVN
Enliven Therapeutics, Inc.
19.3
$60.50 · $4.4B
fundamentals as of
Score gap
54.6
EXEL leads
EXEL
Exelixis, Inc.
73.9
$56.72 · $14.1B
fundamentals as of
At a glance · who leads each dimension, on the model's own rules
- Strongest balance sheetELVN0.00
- Highest qualityEXEL97 / 100
- Largest discount to fair valueEXEL-39%
Side by side · every name on one set of axes
The model, pillar by pillar (0–100 each)
ELVN
stronger →← stronger
EXEL
23
Qualityreturns · margins · balance sheet
97
10
Growthrevenue & earnings expansion
80
31
Valuevaluation vs sector peers
52
EXEL is stronger on 3 of 3 pillars.
Fundamentals, head-to-head
ELVN
EXEL
-$67mF
FCF
$1.2bC+
—
Rev
+9.2%B
0.00A
D/E
0.09B+
—
PEG
2.56C
—
P/E
17.8xA-
Winner per row is the stronger grade; where grades tie, the better figure breaks it. A true tie or a missing value shows no highlight.
Valuation · DCF cross-check
ELVN
EXEL
—
Price vs fair valuelower is cheaper
39% below
—
Growth the price implies10-yr FCF · lower = less priced in
~-2%/yr
—
1-yr DCF upside
+38%
—
5-yr DCF upside
+64%
—
10-yr DCF upside
+108%
The DCF is a cross-check on intrinsic value, separate from the quality-growth score above.
Model signals
ELVN
Why this score
- Diluting shareholders
EXEL
Why this score
- Buying back stock
- Durable high returns
The companies
ELVNEnliven Therapeutics, Inc.
Why now
Biotechnology · market cap $4.4b. Trading near 52-week high of $62.32 — momentum setup, limited technical margin of safety. 10 sell-side analysts rate this a Strong Buy with a mean 1-yr target of $73.90 (implying +22% upside).
Moat
Pharma moat is patent runway + pipeline depth — a single approved molecule funds the next generation of bets. Late-stage trials carry binary readouts that swing valuation 30%+.
Risk
Free cash flow is negative (-$67m) — capital raises or debt issuance likely required; dilution / leverage risk. Trading within 3% of the 52-week high — limited technical margin of safety; a momentum reversal would test conviction. ROE -12% is below the long-run sustainable threshold of ~10% — capital efficiency would need to improve for the equity base to compound at the market rate.
EXELExelixis, Inc.
Why now
Biotechnology · market cap $14.1b. Trading near 52-week high of $57.57 — momentum setup, limited technical margin of safety. 17 sell-side analysts rate this a Buy with a mean 1-yr target of $53.00 (implying -7% upside).
Moat
Net margin 35% is exceptional — pricing-power territory rare outside premium software, branded staples, and specialty pharma. ROE 47% — top-decile capital efficiency. Either pricing leverage, low capital intensity, or aggressive buybacks; the durability story depends on which. FCF converts 136% of net income — earnings translate cleanly into cash, a sign that working capital and capex are well-disciplined.
Risk
Trading within 1% of the 52-week high — limited technical margin of safety; a momentum reversal would test conviction. Trial-readout binary — late-stage clinical trials carry approve/reject outcomes that swing valuation 30%+; the equity is effectively a portfolio of these binary events, not a steady cash-flow business.
Verdict — model-derived comparison
Generating verdict… typically 5–10 seconds
Not investment advice. The Bull Rankings publishes a quantitative ranking model and accompanying analysis for general informational purposes only. Nothing on this page is a recommendation to buy, sell, or hold any security; nothing is personalized to your circumstances, risk tolerance, or tax situation. Investing carries the risk of loss — invest at your own risk and consider consulting a licensed financial professional before acting on anything you read here. See terms and methodology for full disclosures.
Where ELVN and EXEL diverge
On the headline score the gap is 54.6 points in favor of EXEL. The widest single difference is Quality, where EXEL leads by 73.6 points.
- QualityELVN 23.2 · EXEL 96.8EXEL +73.6
- GrowthELVN 10.0 · EXEL 80.0EXEL +70.0
- ValueELVN 31.0 · EXEL 52.2EXEL +21.2
Pillars run 0–100 against sector peers, so a score is a statement about a company relative to its own industry rather than to the other name here. A wide Value gap usually means the market already prices the difference in quality or growth — which is the trade-off this comparison comes down to.